Posted on March 29, 2019 by Sitemaster
We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …
Filed under: Uncategorized | Tagged: checkpoint, CTLA4, immunotherapy, inhibition, PD-1, PD-L1, risk | 1 Comment »
Posted on November 9, 2017 by Sitemaster
Just over a year ago, we reported on a paper by Hearn et al. that had shown that a specific inherited mutation in the HSD3B1 gene seemed to be associated with a more aggressive form of prostate cancer that was less responsive to treatment with androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 1245C, allele, CYP17A1, HSD3B1, inhibition, Treatment, variant | 2 Comments »
Posted on April 30, 2015 by Sitemaster
Alas, our friends at The Daily Telegraph in the UK seem to have managed to hyperinflate some early scientific findings into an overnight cure for prostate cancer in general and metastatic, castration-resistant prostate cancer in particular. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: B cell, checkpoint, inhibition, oxaliplatin, suppression | 8 Comments »
Posted on November 11, 2014 by Sitemaster
According to a news report in The Daily Telegraph (a British newspaper) today, “Prostate cancer could be ‘switched off’ with injection.” However, the research that stimulated this headline has only been conducted in mice, so there is a long way to go before we know if this is a real possibility in man. … READ MORE …
Filed under: Drugs in development | Tagged: angiogenesis, inhibition, SRPK1 | Leave a comment »
Posted on August 7, 2011 by Sitemaster
There are in fact three so-called “isozymes” (slightly different versions) of the human enzyme 5α-steroid reductase. The activity of 5α-reductase-II can be affected by the 5α-reductase inhibitor (5-ARI) finasteride (Proscar); the activity of 5α-reductase-I and -II can be affected by the 5-ARI dutasteride (Avodart), but … READ MORE …
Filed under: Drugs in development, Prevention | Tagged: 5α-reductase, expression, inhibition | 1 Comment »